The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies.
Stephen Maxted Ansell
Research Funding - Celldex
Donald W. Northfelt
No relevant relationships to disclose
Ian Flinn
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Shira Naomi Dinner
No relevant relationships to disclose
Victor Manuel Villalobos
No relevant relationships to disclose
Branimir I. Sikic
Research Funding - Celldex
Matthew Hiram Taylor
No relevant relationships to disclose
Lana Pilja
Employment or Leadership Position - Celldex
Stock Ownership - Celldex
Thomas R. Hawthorne
Employment or Leadership Position - Celldex
Stock Ownership - Celldex
Michael Jay Yellin
Employment or Leadership Position - Celldex
Stock Ownership - Celldex
Tibor Keler
Employment or Leadership Position - Celldex
Stock Ownership - Celldex
Thomas A. Davis
Employment or Leadership Position - Celldex
Stock Ownership - Celldex